Breast Cancer Pipeline Remains Strong, Analysts Say

A new report from Frost & Sullivan has highlighted the unmet need for breast cancer therapies.

The pipeline for breast cancer therapeutics remains strong, despite the existence of around 27 approved drugs for the disease, analysts have said.

Frost & Sullivan's latest report points out that there is still an unmet need for treatments for breast cancer, the second leading cause of cancer-related death in women.

Pharmaceutical companies therefore have a major opportunity and 24 new drugs are expected to be launched for the disease in the US between 2012 and 2017.

This is out of a total of 55 drugs that are currently in the developmental stage for the disease in the US alone.

Jennifer Brice, global pro